Contingencies

9 Months Ended

Sep. 30, 2024

Loss Contingency [Abstract]

Contingencies

Note 9: Contingencies

The following tables summarize the contingencies as of September 30, 2024 and December 31, 2023:

	September 30, 2024	December 31, 2023
Current contingencies	253	3,959
Non-current contingencies	1,070	935
Total contingencies	1,323	4,894

The changes in contingencies are as follows:

	Pension retirement obligations	Collaboration agreement - Loss at completion	Other contingencies	Total
At January 1, 2024	935	2,100	1,859	4,894
Increases in liabilities	87	—	73	159
Used liabilities	—	(1,930)	(1,136)	(3,066)
Reversals of unused liabilities	—	—	(656)	(656)
Net interest related to employee benefits, and unwinding of discount	—	—	—	—
Actuarial gains and losses on defined-benefit plans	33	—	—	33
Currency translation effect	16	(30)	(27)	(41)
At September 30, 2024	1,070	141	112	1,323
Of which current	—	141	112	253
Of which non-current	1,070		—	1,070

In May 2016, the Company entered into a Development Collaboration and License Agreement (the “Collaboration Agreement”) with Societe des Produits Nestle S.A. (formerly, NESTEC S.A.) (“NESTEC”) under which the Company was responsible for leading the development activities of MAG1C up through a pivotal phase 3 clinical program. On October 30, 2023, the Company signed a Mutual Termination Letter Agreement with NESTEC terminating the Collaboration Agreement between the parties. As of September 30, 2024, the accrual for ongoing Clinical study completion totals $0.1 million as compared to $2.1 million as of December 31, 2023 representing our best estimate of the remaining expenses related to the ongoing clinical study.

An amount of $1.8 million reserved for the refurbishment of the previous Montrouge offices was reversed in the second quarter of 2024.

The Company does not hold any plan assets related to long-term employee benefit for any of the periods presented. There have been no significant changes in assumptions for the estimation of the retirement commitments from those disclosed in Note 13 to the consolidated financial statements included in the Annual Report.